These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 3006224)

  • 1. Myeloperoxidase-deficient polymorphonuclear leucocytes (VII): Incidence in untreated myeloproliferative disorders.
    Bendix-Hansen K
    Scand J Haematol; 1986 Jan; 36(1):8-10. PubMed ID: 3006224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of neutrophil alkaline phosphatase (NAP) activity in untreated myeloproliferative syndromes and in leukaemoid reactions.
    Bendix-Hansen K; Bergmann OJ
    Scand J Haematol; 1985 Aug; 35(2):219-24. PubMed ID: 4048868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myeloperoxidase-deficient polymorphonuclear leucocytes. (I) Incidence in untreated myeloid leukaemia, lymphoid leukaemia and normal humans.
    Bendix-Hansen K; Kaspersen Nielsen H
    Scand J Haematol; 1983 May; 30(5):415-9. PubMed ID: 6304866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myeloperoxidase-deficient polymorphonuclear leucocytes. (V): Relation to FAB-classification and neutrophil alkaline phosphatase activity in primary myelodysplastic syndromes.
    Bendix-Hansen K; Kerndrup G
    Scand J Haematol; 1985 Aug; 35(2):197-200. PubMed ID: 2996123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The activity of the alkaline phosphatase of neutrophils in myeloproliferative diseases].
    Vakulenko AD; Shubich MG
    Ter Arkh; 1966 Feb; 38(2):66-9. PubMed ID: 5235224
    [No Abstract]   [Full Text] [Related]  

  • 6. Myeloperoxidase deficient polymorphonuclear leucocytes in leukaemia and allied disorders.
    Bendix-Hansen K
    Dan Med Bull; 1988 Dec; 35(6):501-20. PubMed ID: 2851415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutrophil 5-nucleotidase reaction in chronic myelogenous leukemia, myelofibrosis with myeloid metaplasia, and polycythemia vera.
    Tsavaris NB; Pangalis GA
    Ann Hematol; 1998 Jan; 76(1):1-5. PubMed ID: 9486917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitation of RNA-dependent platelet DNA polymerase in patients with myeloproliferative disorders.
    Strayer DR; Brodsky I; Caranfa MJ; Gillespie DH
    Br J Haematol; 1982 Mar; 50(3):521-30. PubMed ID: 6175335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies of neutrophil and monocyte oxidative responses in polycythaemia vera and related myeloproliferative disorders.
    Samuelsson J; Forslid J; Hed J; Palmblad J
    Br J Haematol; 1994 Jul; 87(3):464-70. PubMed ID: 7993785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [An improved method for biochemical measurement of the activity of neutrophil alkaline phosphatase and its application to myeloproliferative disorders].
    Tokuda M; Kawanishi K; Irino S
    Rinsho Ketsueki; 1991 Aug; 32(8):838-43. PubMed ID: 1942523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Muramidase activity in leukemia and myeloproliferative disorders.
    Skarin AT; Matsuo Y; Moloney WC
    Oncology; 1973; 27(5):406-14. PubMed ID: 4515747
    [No Abstract]   [Full Text] [Related]  

  • 12. Myeloperoxidase-deficient polymorphonuclear leucocytes. Longitudinal study during the preremission--and the remission phase in acute myeloid leukaemia. Comparison to neutrophil alkaline phosphatase (NAP) activity.
    Bendix-Hansen K
    Blut; 1986 Apr; 52(4):237-42. PubMed ID: 3008894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Muramidase in myeloproliferative disorders terminating in acute leukemia.
    Skarin AT; Matsuo Y; Moloney WC
    Cancer; 1972 May; 29(5):1336-42. PubMed ID: 4502496
    [No Abstract]   [Full Text] [Related]  

  • 14. [MYELOPROLIFERATIVE SYNDROMES].
    PIRESWDA F
    Folha Med; 1964 Apr; 48():195-201. PubMed ID: 14271209
    [No Abstract]   [Full Text] [Related]  

  • 15. Quantification of JAK2V617F mutation by next-generation sequencing technology.
    Abdelhamid E; Figeac M; Renneville A; Quief S; Villenet C; Boyer T; Nibourel O; Coiteux V; Cassinat B; Lippert E; Helevaut N; Soua Z; Preudhomme C
    Am J Hematol; 2013 Jun; 88(6):536-7. PubMed ID: 23553621
    [No Abstract]   [Full Text] [Related]  

  • 16. Classic myeloproliferative neoplasms in Singapore: A population-based study on incidence, trends, and survival from 1968 to 2017.
    Htun HL; Lian W; Wong J; Tan EJ; Foo LL; Ong KH; Lim WY
    Cancer Epidemiol; 2022 Aug; 79():102175. PubMed ID: 35569302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
    Tefferi A
    Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myeloperoxidase-deficient polymorphonuclear leucocytes. (IV): Relation to FAB-classification in acute myeloid leukaemia.
    Bendix-Hansen K; Nielsen HK
    Scand J Haematol; 1985 Aug; 35(2):174-7. PubMed ID: 2996122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinico-Pathological Profile And Outcomes Of Patients With Polycythaemia Vera, Essential Thrombocythaemia And Idiopathic Myelofibrosis: A Tertiary Care Center Experience From Southern Pakistan.
    Shaikh MS; Shaikh MU; Adil SN; Khurshid M; Ahmed ZA
    J Ayub Med Coll Abbottabad; 2016; 28(2):293-297. PubMed ID: 28718562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Diagnostic and pathogenetic significance of some cytogenetic and cythochemical findings (leukocyte alkaline phosphatase) in systemic hemopathies with myeloproliferative tendencies].
    Cacciola E; Giustolisi R
    Haematologica; 1970; 55(5):311-32. PubMed ID: 4995787
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.